drugset / Trial / NCT01514851
Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (Lanthanum Carbonate) in patients with hyperphosphatemia undergoing hemodialysis in a randomized, double-blind, parallel group study in comparison with Calcium carbonate.
Timeline
- Start
- 2006-01
- Primary completion
- 2006-05
- Completion
- 2006-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Calcium carbonate | Other / unclassified | 1500 mg | — |
| Comparator | Calcium carbonate | Other / unclassified | 4500 mg | — |
| Subject | Lanthanum Carbonate | Other / unclassified | 750 mg | — |
| Subject | Lanthanum Carbonate | Other / unclassified | 2250 mg | — |